METHODS

Design
 A retrospective cohort study of T2DM patients in England and Wales initiating GLP-1 therapies for the first time. NICE GLP-1 recommendations are not formally followed in Scotland or Northern Ireland.
Study Period
 Prescribing of GLP-1, assessed on or after publication of the relevant NICE guidance or guideline. 
Eligibility Criteria
 7,133 patients ≥40 years of age at GLP-1 initiation with ≥12 months of CPRD history prior to first GLP-1 prescription.
 Patients with more than one type of GLP-1 recorded at initiation were excluded as were patients with record of pregnancy documented up to 12 months prior to GLP-1 initiation.
Measures
 Treatment with GLP-1 mimetic categorized as monotherapy, dual, triple or other therapies.
-Treatment categories were based on prescribed T2DM drug classes only.
-Monotherapy and combination therapy were defined as the number of drug classes prescribed within a sliding 30-day interval.
-'Other therapies' included GLP-1 as part of quadruple combination therapy, or any use with insulin.
 HbA1c and body mass index [BMI] up to 6 months prior to initiating GLP-1.
Outcomes of Interest
 The proportion of patients initiating GLP-1 as part of NICE recommended dual or triple therapy. 
LIMITATIONS
• Control of blood glucose levels remains the cornerstone of managing Type 2 diabetes mellitus (T2DM).
• Clinical trials have demonstrated the efficacy of glucagon-like peptide-1 (GLP-1) mimetics in lowering blood glucose and resulting in meaningful weight loss.
[1]
• The UK National Institute of Health and Care Excellence (NICE) has published guidelines/guidance for prescribing GLP-1 therapies for patients with T2DM. [2-4]
• Such national guidelines/guidance offer best practice advice on how decisions about prescribed medicines should be made, including criteria for initiating treatment.
• Clinicians adherence to NICE prescribing guidelines are likely to result in greater clinical benefit to patients, and efficient use of resources in the NHS.  Greater efforts are needed to ensure that HbA1c and BMI are routinely measured prior to initiating GLP-1.
 Key priorities highlighted by the NICE guidelines need to be reinforced to improve adherence to NICE recommendations.
 Further research is needed to identify possible causes of non-adherence to NICE treatment guidelines.
 T2DM regimen categories were based on prescriptions only and not on actual duration of therapies . This may have resulted in the misclassification of treatment categories.
 Due to lack of data on contraindications/ intolerance, we were unable to fully assess adherence to NICE recommendations for initiating GLP-1 as dual therapy.
T2DM prescribing outside of the primary care setting were not included.
 HbA1c and BMI measurements were not always available prior to GLP-1 initiation. Ethnicity data was not widely available and not used in assessing NICE BMI criterion. 
